Tools & Documentations

Our publications

Since its creation, Institut Roche has translated its expertise into numerous successful scientific publications

Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study. Annals of clinical and translational neurology, 8(2), 359–373.

Annoussamy, M., Seferian, A. M., Daron, A., Péréon, Y., Cances, C., Vuillerot, C., De Waele, L., Laugel, V., Schara, U., Gidaro, T., Lilien, C., Hogrel, J. Y., Carlier, P., Fournier, E., Lowes, L., Gorni, K., Ly-Le Moal, M., Hellbach, N., Seabrook, T., Czech, C., … NatHis-SMA study group (2021).

See More

DNA repair-based classification of melanoma cell lines reveals an effect of mutations in BRAF and NRAS driver genes on DNA repair capacity. Biorxiv.

Sauvaigo, S., Benkhiat, M., Braisaz, F., Girard, J., Libert, S., Mouret, S., de Fraipont, F., Aspord, C., Bouquet, F., & Leccia, M. T. (2020).

See More

Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment. Journal of pharmacokinetics and pharmacodynamics, 47(6), 613–625.

Mercier, F., Kerioui, M., Desmée, S., Guedj, J., Krieter, O., & Bruno, R. (2020).

See More

Bayesian inference using Hamiltonian Monte-Carlo algorithm for nonlinear joint modeling in the context of cancer immunotherapy. Statistics in medicine, 39(30), 4853–4868.

Kerioui, M., Mercier, F., Bertrand, J., Tardivon, C., Bruno, R., Guedj, J., & Desmée, S. (2020).

See More

“Reading the Mind in the Eyes” in Autistic Adults is Modulated by Valence and Difficulty : An InFoR Study. Autism Research, 14(2), 380-388.

Baltazar, M., Geoffray, M., Chatham, C., Bouvard, M., Martinez Teruel, A., Monnet, D., Scheid, I., Murzi, E., Couffin-Cadiergues, S., Umbricht, D., Murtagh, L., Delorme, R., Ly Le-Moal, M., Leboyer, M., & Amestoy, A. (2020).

See More

Low expression of ANT1 confers oncogenic properties to rhabdomyosarcoma tumor cells by modulating metabolism and death pathways. Cell Death Discovery, 6(1).

Vial, J., Huchedé, P., Fagault, S., Basset, F., Rossi, M., Geoffray, J., Soldati, H., Bisaccia, J., Elsensohn, M. H., Creveaux, M., Neves, D., Blay, J. Y., Fauvelle, F., Bouquet, F., Streichenberger, N., Corradini, N., Bergeron, C., Maucort-Boulch, D., Castets, P.,. . . Castets, M. (2020).

See More

IDO Targeting in Sarcoma : Biological and Clinical Implications. Frontiers in Immunology, 11.

Nafia, I., Toulmonde, M., Bortolotto, D., Chaibi, A., Bodet, D., Rey, C., Velasco, V., Larmonier, C. B., Cerf, L., Adam, J., le Loarer, F., Savina, A., Bessede, A., & Italiano, A. (2020).

See More

Prototyping Trastuzumab Docetaxel Immunoliposomes with a New FCM-Based Method to Quantify Optimal Antibody Density on Nanoparticles. Sci Rep 10, 4147 (2020).

Rodallec, A., Franco, C., Robert, S. et al.

See More

Tumor uptake and associated greater efficacy of anti-Her2 immunoliposome does not rely on Her2 expression status: study of a docetaxel-trastuzumab immunoliposome on Her2+ breast cancer model (SKBR3). Anti-cancer drugs, 31(5), 463–472.

Rodallec, A., Sicard, G., Giacometti, S., Carre, M., Maia, T., Valette, M., Bouquet, F., Savina, A., Lacarelle, B., Ciccolini, J., & Fanciullino, R. (2020).

See More
More contents :

Results :18/90